Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Finished Goods (2016 - 2018)

Lifecore Biomedical, Inc. \De\ has reported Finished Goods over the past 7 years, most recently at $13.9 million for Q4 2018.

  • For Q4 2018, Finished Goods rose 7.93% year-over-year to $13.9 million; the TTM value through Nov 2018 reached $13.9 million, up 7.93%, while the annual FY2018 figure was $12.9 million, 28.42% up from the prior year.
  • Finished Goods for Q4 2018 was $13.9 million at Lifecore Biomedical, Inc. \De\, up from $12.9 million in the prior quarter.
  • Over five years, Finished Goods peaked at $17.1 million in Q3 2016 and troughed at $10.0 million in Q2 2017.
  • A 5-year average of $12.7 million and a median of $12.8 million in 2016 define the central range for Finished Goods.
  • Biggest five-year swings in Finished Goods: decreased 26.16% in 2017 and later grew 28.42% in 2018.
  • Year by year, Finished Goods stood at $14.3 million in 2014, then fell by 0.81% to $14.2 million in 2015, then dropped by 24.33% to $10.7 million in 2016, then rose by 20.2% to $12.9 million in 2017, then increased by 7.93% to $13.9 million in 2018.
  • Business Quant data shows Finished Goods for LFCR at $13.9 million in Q4 2018, $12.9 million in Q3 2018, and $12.9 million in Q2 2018.